It is also worth noting that other treatment alternatives targeting angiopoietin-like 3 (ANGPTL3) have emerged as candidates for FH treatment, especially for individuals with refractory FH [110]. This evidence concerns the gene ANGPTL3 and familial hyperaldosteronism.